AmyScan Healthcare develops ultra-sensitive diagnostic tests capable of detecting and amplifying trace levels of disease-specific amyloid seeds in blood and other body fluids. Using patented IIT Bombay technology, the company is launching the world’s first blood test for easy, accurate and cost-effective detection of Parkinson’s disease. This solution overcomes the limitations of symptom-based diagnosis and expensive imaging, enabling true early detection and biomarker-based staging of disease. The platform is fully scalable, with the potential to create blood tests for other major disorders, including Alzheimer’s disease, positioning AmyScan as a leader in next-generation molecular diagnostics.